)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Dianthus Therapeutics
Dianthus Therapeutics (DNTH) investor relations material
Dianthus Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Pipeline and clinical program updates
Advancing two clinical-stage autoimmune therapeutics focused on infrequent, self-administered subcutaneous dosing.
Claseprubart targets the classical complement pathway with positive phase 2 data in myasthenia gravis (MG) and proof of concept in CIDP and MMN.
DNTH212, a bispecific BDCA2 and BAFF/APRIL inhibitor, has started phase 1 trials, showing superior in vitro and NHP data versus competitors.
Both programs aim for best-in-class efficacy, safety, and patient convenience.
Phase 3 for claseprubart in MG to include every-two-week and every-four-week dosing arms.
Efficacy, safety, and differentiation
Claseprubart demonstrated robust, rapid, and statistically significant efficacy in MG, with potential for superior efficacy over C5 inhibitors.
Open-label extension data support equivalent efficacy for monthly dosing.
No Box warning or REMS program anticipated, differentiating from other complement inhibitors.
Head-to-head in vitro data show claseprubart is more potent than riliprubart and empasiprubart.
DNTH212 aims for enhanced efficacy in diseases driven by both innate and adaptive immunity, with no new safety signals expected.
Market opportunities and competitive landscape
Targeting over 150,000 patients in the US across MG, CIDP, and MMN.
MMN market is small but offers blockbuster potential due to lack of competition and high pricing.
Only one other biologic (empasiprubart) is being studied in MMN; claseprubart is more potent and more convenient.
Competitors like Argenx and Sanofi are running head-to-head trials versus IVIG, signaling belief in complement inhibition's potential.
DNTH212 will prioritize indications such as SLE, dermatomyositis, or Sjogren’s, with updates expected in the first half of the year.
Clasibobart's differentiation vs C5s in MG
Clarify CIDP trial design vs ADHERE
MMN market opportunity and Clasibobart's edge
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Dianthus Therapeutics earnings date
Q4 202513 Mar, 2026
Dianthus Therapeutics
Next Dianthus Therapeutics earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Dianthus Therapeutics Inc., operating under the ticker DNTH, is a clinical-stage biotechnology company based in New York, New York. The company focuses on designing, developing, and delivering innovative monoclonal antibodies intended for the treatment of severe autoimmune and inflammatory diseases. Their key developmental product is DNTH103, currently in clinical trials, targeted at conditions such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage